EverHint Lens - Day One Biopharmaceuticals, Inc. (DAWN) - +65.85% Stock Analysis - March 06, 2026

Analysis Date: 2026-03-06
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

Executive Summary

Day One Biopharmaceuticals, Inc. is currently trading at $21.20 (🟢 +65.85% today) with a market capitalization of $2.19B.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.

Price & Valuation

Current Price: $21.20 (at 1:38 PM ET)
Current Volume: 70.9M
Day Range: $21.09 - $21.20
52-Week Range: $5.63 - $21.20
P/E Ratio: N/A

DCF Valuation: Undervalued

• Intrinsic Value (Unlevered DCF): $61.86
• Current Price: $21.20
• Discount/Premium: +191.9%

Levered DCF: $25.32 (+19.5%)

⚠️ High divergence between levered and unlevered DCF
⚠️ DCF shows extreme valuation gap (>100%)

DCF analysis suggests the stock may be trading at a 191.9% discount to its intrinsic value.

DCF values calculated as of 2026-03-06. Underlying assumptions are not disclosed by the data provider. Levered vs unlevered can diverge materially for highly levered companies.

Market Context

Healthcare Sector: -0.0679% | Sector P/E: 31.47

Major Indices:

• S&P 500: $6756.59 (🔴 -1.09%)
• NASDAQ Composite: $22526.34 (🔴 -0.98%)
• Dow Jones Industrial Average: $47376.90 (🔴 -1.20%)

Peer Comparison

Peer comparison (11 companies):

• DAWN - Day One Biopharmaceuticals, Inc. ($21.20, +65.8%, $2.19B) ← Current
• ERAS - Erasca, Inc. ($15.17, -2.4%, $4.70B)
• TYRA - Tyra Biosciences, Inc. ($34.47, -0.2%, $1.84B)
• VIR - Vir Biotechnology, Inc. ($9.14, +0.5%, $1.28B)
• AVBP - ArriVent BioPharma, Inc. Common Stock ($24.27, -3.9%, $1.00B)
• GERN - Geron Corporation ($1.56, +9.8%, $995M)
• VALN - Valneva SE ($10.50, -5.5%, $903M)
• ARVN - Arvinas, Inc. ($13.07, -4.7%, $839M)
• ATXS - Astria Therapeutics, Inc. ($12.58, 0.0%, $718M)
• REPL - Replimune Group, Inc. ($7.46, +6.0%, $616M)
• RZLT - Rezolute, Inc. ($3.13, +0.2%, $300M)

Financial Performance

Latest Quarter (2025-12-31):

• Revenue: $53.72M
• Net Income: $-21.28M
• EPS: $-0.21
• Revenue Growth (QoQ): +35.0%

Earnings Calendar

Next Earnings Report: 2026-05-13 (After Market Close)

• EPS Estimate: $-0.25
• Revenue Estimate: $0.05B

Most Recent Report: 2026-02-24

• EPS: $-0.21 (Est: $-0.17) ✗ Miss
• Revenue: $0.05B

Historical Data: 25 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $26.00 (+22.7% upside)
• Range: $26.00 - $26.00
• Median: $26.00

Next Quarter Estimates (2027-12-31):

• Revenue: $87.20M
• EPS: $-0.14

Analyst Consensus

Overall Rating: Buy

Rating Distribution (92 total ratings):

• 🟢 Buy/Outperform: 88 (95.7%)
• ⚪ Hold/Neutral: 0 (0.0%)
• 🔴 Sell/Underperform: 2 (2.2%)

Recent Analyst Actions:

• HC Wainwright & Co. (2026-02-25): Maintained Buy
• Wedbush (2026-02-25): Maintained Outperform
• Needham (2026-02-25): Maintained Buy
• HC Wainwright & Co. (2025-11-24): Maintained Buy
• Needham (2025-11-24): Maintained Buy

Consensus based on 92 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 6 trading signal(s) in the last 60 days:

• 2026-03-04: Ema10 Ema30 - EMA10_x_EMA30_Buy @ $12.87
• 2026-03-04: Momentum Swing - breakout @ $12.87
• 2026-01-15: Dip Bounce V2 Reclaim - RECLAIM_LONG @ $10.50
• 2026-01-14: Dip Bounce V2 Reclaim - RECLAIM_LONG @ $10.73
• 2026-01-13: Dip Bounce V2 Reclaim - RECLAIM_LONG @ $10.59

Insider Activity

Recent Transactions (Last 10):

• Buys: 5
• Sells: 5

Notable Transactions:

• 2026-02-15: Merendino Lauren - Sell (Option Exercise, 4,625 shares)
• 2026-02-15: Merendino Lauren - Buy (Option Exercise, 4,625 shares)
• 2026-02-15: Merendino Lauren - Buy (Option Exercise, 3,687 shares)

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

News sentiment for Day One Biopharmaceuticals (DAWN) is strongly positive, highlighted by the $2.5B acquisition by Servier at $21.50 per share that drove shares higher, robust OJEMDA revenue growth exceeding 170% year-over-year, and multiple 'Strong Buy' analyst ratings with significant upside potential. Positive developments include the Mersana acquisition and promising clinical data. Shareholder investigations into the deal's fairness add slight caution but do not overshadow the bullish momentum.

Key Themes:

• Servier Acquisition
• OJEMDA Revenue Growth
• Analyst Strong Buy Ratings

Sentiment: Positive (92% confidence)

Reddit Sentiment

Community Discussion (last 30 days from r/wallstreetbets, r/stocks, r/investing):

Overall Sentiment: Strongly Bullish 📈📈 (Score: 0.993)

Post Analysis:

• Total posts: 1
• Bullish: 1 (100.0%)
• Bearish: 0 (0.0%)
• Neutral: 0 (0.0%)
• Total engagement: 51 (upvotes + comments)

Note: Sentiment score ranges from -1.0 (very bearish) to +1.0 (very bullish), weighted by post engagement.

Recent News

5 most recent articles covering DAWN:

• $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) (prnewswire.com, 2026-03-06) — Read more
• DAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders (businesswire.com, 2026-03-06) — Read more
• Day One Shares Surge After $2.5B Servier Deal (benzinga.com, 2026-03-06) — Read more
• Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion (reuters.com, 2026-03-06) — Read more
• Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio (globenewswire.com, 2026-03-06) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-03-06 10:38:42 AM PST

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.